ArticleThe Journal of biological chemistry2025
Altering the ligand specificity of DectiSomes.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human Dectin-1- and Dectin-2-targeted DectiSomes are effective against diverse pathogenic fungi.Antimicrobial agents and chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
DectiSomes are drug-loaded liposomes coated with pathogen receptors, such as the C-type lectins (CTL) Dectin-2 (D2) and Dectin-3 (D3, MCL). Floating on the surface of DectiSomes, the carbohydrate recognition domains (CRDs) of these CTLs form dimers that bind their cognate oligoglycan ligands. We have shown previously that amphotericin B (AmB)-loaded DectiSomes, D2-AmB-LLs, and D3-AmB-LLs, are effective at binding and killing diverse pathogenic fungi. The best-known ligands of Dectin-2 and Dectin-3 in the Candida albicans cell wall and exopolysaccharide matrix include a wide variety of oligomannans. When D2-AmB-LLs or D3-AmB-LLs were labeled in their lumen with complementary green and red fluorescent proteins, Venus and mCherry, they bound the same overlapping regions of oligoglycans in C. albicans colonies. By contrast, when D2-AmB-LLs and D3-AmB-LLs were labeled on their membrane surfaces with complementary pairs of the small fluorophores FITC and Rhodamine B or with Venus and mCherry, they bound mostly nonoverlapping sets of ligands. When the Dectin-2 and Dectin-3 proteins were labeled with the complementary pairs of FITC and Rhodamine, they also bound primarily distinct ligands. We proposed several models to explain these alterations in Dectin and DectiSome ligand specificity. These findings also raise important questions about the ligand binding properties of immuno-liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.